BRIDGEWATER, N.J., January 23, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has ...

According to Business Research Insights the Memantine Hydrochloride Tablets Market expected to exhibit a CAGR of 5.9% by 2033. The "Memantine Hydrochloride Tablets Market" Research is your essential ...

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...

It is a therapeutic equivalent generic version of NAMENDA (memantine HCl) tablets in the US market Dr Reddy’s Laboratories has launched memantine hydrochloride tablets USP, 5 mg and 10 mg, a ...

Actavis and Adamas announced that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric (memantine HCl extended-release and donepezil HCl) capsules for the ...

DUBLIN, May 22, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that a panel of the U.S. Court of Appeals for the Second Circuit has issued a ruling upholding a December 15, 2014 ...

The Business Research Company's Memantine HCl Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On ...

NEW YORK, Feb. 5 -- Forest Laboratories, Inc. (NYSE: FRX - News) today announced preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda®, a twice-daily immediate- ...

Memantine is a non-acetyl cholinesterase inhibitor that helps in Alzheimer's disease therapy. The medicine was approved for sale in Europe in 2002 and the United States Food and Drug Administration ...